Dyadic International, Inc. (DYAI)
| Market Cap | 152.53M |
| Revenue (ttm) | 1.69M |
| Net Income (ttm) | -9.10M |
| Shares Out | 27.48M |
| EPS (ttm) | -0.33 |
| PE Ratio | n/a |
| Forward PE | 14.47 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 19 |
| Last Price | $5.56 |
| Previous Close | $5.31 |
| Change ($) | 0.25 |
| Change (%) | 4.71% |
| Day's Open | 5.39 |
| Day's Range | 5.32 - 5.60 |
| Day's Volume | 87,152 |
| 52-Week Range | 2.58 - 10.26 |
JUPITER, FL / ACCESSWIRE / January 11, 2021 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 g...
Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q2 2020 Results - Earnings Call Transcript
This small-cap stock is developing a technology that could revolutionize biotech.
Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q1 2020 Results - Earnings Call Transcript
Dyadic International: The Pandemic Changes Everything
Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q4 2019 Results - Earnings Call Transcript
Dyadic International, Inc. (NASDAQ: DYAI) shares are trading higher on Thursday, after the company announced its platform is to be used by the Israeli Research Institution to develop a treatme...
Monday morning brought a huge sell-off in the market as more and more people are concerned about the growing impact of this new coronavirus.
Dyadic International: Disrupting Biopharma Delivery And Costs
Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q3 2019 Results - Earnings Call Transcript
Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q2 2019 Results - Earnings Call Transcript
Company’s lead product promises to greatly speed development and reduce costs of producing biologic drugs, which is currently being tested by major collaborators and at least two big pharma pl...
About DYAI
Dyadic International, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. It has a research... [Read more...]
| Industry Biotechnology | IPO Date Nov 5, 2004 |
| CEO Mark A. Emalfarb | Employees 6 |
| Stock Exchange NASDAQ | Ticker Symbol DYAI |
Financial Performance
In 2019, DYAI's revenue was $1.68 million, an increase of 29.77% compared to the previous year's $1.30 million. Losses were -$8.31 million, 46.0% more than in 2018.
Analyst Forecasts
According to one analyst, the rating for DYAI stock is "Strong Buy" and the 12-month stock price forecast is 11.00.